文献速递药物不良反应与药物警戒

消费者对天然保健品行业在药物警戒中作用的看法:新西兰定性研究

Consumer Views on the Role of the Natural Health Products (NHPs) Industry in Pharmacovigilance for NHPs: A Qualitative Study in New Zealand.
PubMed 文献 · Drug Saf · 2026-10-02

该定性研究通过在线一对一访谈19名新西兰天然保健品消费者,探讨其对行业参与药物警戒的看法与经验。研究发现消费者对行业处理不良反应报告缺乏信任,自我负责态度成为参与障碍,并建议提升风险认知与报告渠道透明度。

要点

  • 消费者常自我选择天然保健品且缺乏专业人员监督。
  • 消费者对行业处理不良反应报告信任度低,因利益冲突与透明度不足。
  • 需提高风险认知、报告渠道知晓率及行业透明度以促进药物警戒。

核心结论

  • 消费者与天然保健品行业在药物警戒方面互动极少,自我负责与不信任是主要障碍。

研究设计与样本

  • 定性研究,对19名新西兰天然保健品消费者进行半结构化在线一对一访谈,采用归纳法分析。

主要发现

  • 受访者自我选择天然保健品,对不良反应及向行业报告的经验有限。
  • 受访者因感知利益冲突和缺乏透明度而不信任行业处理不良反应报告。
  • 受访者对天然保健品法规认知低,但期望监管平衡产品可及性与安全控制。

临床怎么用

  • 临床药师应主动询问患者天然保健品使用情况并告知不良反应报告渠道。
  • 鼓励消费者向监管机构或行业报告天然保健品相关不良反应。
  • 关注消费者对行业透明度的疑虑,提供客观的风险沟通。

局限性

  • 样本量小(n=19),仅为定性研究,结果需定量研究验证。
  • 研究仅限新西兰消费者,外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pharmacovigilance (safety monitoring) for natural health products (NHPs) is essential for consumer health protection. However, pharmacovigilance for NHPs is under-researched, especially regarding consumer involvement and the contributions of the NHPs industry. OBJECTIVES: This qualitative study aimed to explore consumers' views, experiences, and awareness of the NHPs industry's contributions to pharmacovigilance for NHPs in New Zealand. METHODS: One-on-one online interviews were conducted with NHP consumers (n = 19) using a semi-structured interview schedule with the following domains: (1) meaning of terms (NHPs and pharmacovigilance); (2) pharmacovigilance for NHPs (including experiences with reporting adverse drug reactions (ADRs) to the NHPs industry); (3) views on NHP regulations and pharmacovigilance regulatory requirements for the NHPs industry; (4) a proposed active surveillance study for NHPs. Interviews were recorded, transcribed verbatim, and analysed inductively. RESULTS: Five main themes were identified: (1) right to choose; (2) trust enables engagement; (3) considering information; (4) rationalising consumer protection; (5) perceiving and navigating risk. Participants exercised autonomy to self-select NHPs. Participants had limited experience with ADRs (associated with NHP use) and with reporting ADRs to the NHPs industry. Despite acknowledging that ethical standards varied across companies, participants expressed distrust of the industry's handling of ADRs, due to perceived conflicts of interest and a lack of transparency. Participants' self-responsibility, underscored by autonomy and lack of trust in the industry, appeared to be significant barriers to the industry's involvement in pharmacovigilance for NHPs. Despite low awareness of NHP regulations, participants held expectations for regulatory requirements that balance product accessibility and safety controls. CONCLUSION: Participants (consumers of NHPs) had minimal engagement with the NHPs industry regarding pharmacovigilance. Raising awareness of the potential harms associated with NHP use, improving knowledge of channels for reporting ADRs, and fostering trust in the industry's handling of ADR reports could empower consumers and enable the industry to assume a more active and significant role in pharmacovigilance for NHPs. Quantitative studies involving larger samples of NHP consumers are necessary to corroborate these findings. Safety monitoring (i.e., pharmacovigilance) for natural health products (NHPs) is essential for consumer health protection. Companies that manufacture and market NHPs are key stakeholders in monitoring the safety of their products, alongside consumers, health professionals, regulators, and natural-health practitioners. Online interviews were conducted with 19 NHP consumers to explore their experiences with and views on the involvement of NHP companies with pharmacovigilance for NHPs, and related regulations for NHPs, in New Zealand. Many participants reported self-selecting NHPs without health professional oversight. Participants had limited experience with adverse reactions associated with NHP use and with reporting these to NHP companies. Participants often do not, or would not, report adverse reactions to NHP companies. This may be because some participants feel personally responsible for using NHPs and doubt that NHP companies would handle such reports responsibly. Despite having low awareness of existing regulations for NHPs, participants expressed support for regulations that safeguard consumer rights and safety, enable informed purchasing decisions, and maintain consumer right to choose and access products. Public health strategies to encourage consumers to report adverse reactions and enable NHP companies to play a greater role in pharmacovigilance should focus on increasing understanding about the potential risks associated with NHPs use, raising awareness of adverse reaction reporting, and supporting NHP companies in building trust and transparency in handling adverse reaction reports. Surveys involving more people are needed to examine whether these interview findings reflect the views of New Zealand consumers more broadly.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Lim XY, Scahill S, Ram S, et al. Consumer Views on the Role of the Natural Health Products (NHPs) Industry in Pharmacovigilance for NHPs: A Qualitative Study in New Zealand. Drug Saf. 2026. PMID: 42827217. doi:10.1007/s40264-026-01732-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。